Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document
Methodological detailsglobal expert panel, evidence summary with expert opinion, Evidence mainly case reports/series and review articles; expert opinion used where no published data
- Global expert panel
- Evidence summary with expert opinion
- Evidence mainly case reports/series and review articles; expert opinion used where no published data
Recommendations
As issued by the authors
Denosumab is effective for RANKL-mediated disorders in children and adolescents but often not curative; in some cases best used with surgical or other medical treatments
Careful multidisciplinary planning is required to define treatment goals, with expert oversight to manage the risk of mineral abnormalities
Original publication
Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document. J Clin Endocrinol Metab. Published 2 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →